Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer

(2014) Paul A. VanderLaan et al.   LUNG CANCER

Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies

(2013) Veena M. Singh et al.   Annals of Diagnostic Pathology

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer

(2013) Eiko Theodora Browning et al.   Journal of Thoracic Oncology

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

(2013) Soyeon Kim et al.   Journal of Thoracic Oncology

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer

(2012) Robert C. Doebele et al.   CANCER

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Toward Improved Understanding of the Ethical and Clinical Issues Surrounding Mandatory Research Biopsies

(2012) Jeffrey Peppercorn   JOURNAL OF CLINICAL ONCOLOGY

Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?

(2012) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR mutations in circulating tumour DNA

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

(2011) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

(2011) Yasushi Yatabe et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer

(2010) F. R. Hirsch et al.   CLINICAL CANCER RESEARCH

Biomarkers Are Here to Stay for Clinical Research and Standard Care

(2010) Paul A. Bunn et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

(2008) J. Bean et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies

(2008) Michael J Thun et al.   PLOS MEDICINE